Makoto Nishio

50PUBLICATIONS
140CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Aug 11, 2026
Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis.

|May 14, 2026
Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.

|Apr 21, 2026
Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.

|Feb 02, 2026
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab.

Atsuto Mouri, Hiroshi Kagamu, Koji Tamada

|Jan 29, 2026
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

Jong-Seok Lee, Shunichi Sugawara, Jin-Hyoung Kang

|Dec 11, 2025
Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2).

Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi

Pageof 9

Frequent Collaborators

6 joint publications

Yasushi Goto

6 joint publications

Hidetoshi Hayashi

6 joint publications

Ryohei Katayama

5 joint publications

Kazuto Nishio